FIELD: medicine.
SUBSTANCE: for the purpose of differential diagnosis of guiding positive and negative semiology in the schizophrenic patients, activity of the enzyme superoxide dismutase in blood cells of the schizophrenic patients is determined. If superoxide dismutase activity is more than 2.6 U/mg of protein, the patient is diagnosed with schizophrenia with guiding negative semiology; and if superoxide dismutase activity is less than 2.5 U/mg of protein, the patient is diagnosed with schizophrenia with guiding positive semiology.
EFFECT: higher diagnostic accuracy in guiding positive and negative semiology in the schizophrenic patients by means of laboratory techniques, and enabled personalising therapeutic approach taking into consideration paraclinic findings.
2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LABORATORY METHOD FOR DIAGNOSIS OF LEADING NEGATIVE SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA | 2015 |
|
RU2578957C1 |
| LABORATORY DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR ENDOGENOUS PSYCHOSIS | 2013 |
|
RU2522236C1 |
| METHOD FOR PREDICTION OF RISK OF DELAYED DYSKINESIA ACCOMPANYING NEUROLEPTIC THERAPY IN SCHIZOPHRENICS | 2010 |
|
RU2447832C1 |
| METHOD OF EFFICIENCY FORECAST FOR RESIDUAL SHIZOPHRENIA TREATMENT BY ATYPICAL NEUROLEPTIC QUETIAPINE | 2007 |
|
RU2349918C1 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING RESIDUAL SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTICS | 2006 |
|
RU2319155C2 |
| METHOD FOR PREDICTING THE EFFICIENCY OF TREATING PATIENTS WITH SCHIZOPHRENIA WITH ATYPICAL NEUROLEPTIC QUETIAPIN (SEROQUEL) | 2005 |
|
RU2289137C1 |
| METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS IN SCHIZOPHRENIC PATIENTS | 2014 |
|
RU2546021C1 |
| METHOD FOR ASSESSING SEVERITY OF CURRENT DEPRESSIVE EPISODE IN PATIENTS WITH RECURRENT DEPRESSIVE DISORDER | 2013 |
|
RU2540491C1 |
| PROTEINS DCLK1 AND RIPK1 BIOMARKERS OF SIMPLE SCHIZOPHRENIA | 2021 |
|
RU2788149C1 |
| METHOD FOR PREDICTION OF EFFICACY OF LADASTEN THERAPY OF ORGANIC ASTHENIC DISORDERS | 2011 |
|
RU2459208C1 |
